100
Participants
Start Date
September 21, 2024
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
VSL#3
VSL#3 450 billion CFU/sachet
Placebo
Placebo sachets with maltose, cornstarch and dioxide
Vedolizumab
Patients will start combined therapy with vedolizumab and VSL#3 or placebo at the same time. Vedolizumab will be administered according to clinical practice with the following schedule: 300 mg intravenously on Baseline (Day 1 / Week 0) and Weeks 2, 6, and 14, with a flexibility of ±3 days relative to the start of VSL#3 administration.
NOT_YET_RECRUITING
The Seventh Medical Center, PLA General Hospital, Beijing
RECRUITING
Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou
NOT_YET_RECRUITING
2nd Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
NOT_YET_RECRUITING
Huzhou City Central Hospital, Huzhou
NOT_YET_RECRUITING
Jinhua City Central Hospital, Jinhua
NOT_YET_RECRUITING
Quzhou City People's Hospital, Quzhou
NOT_YET_RECRUITING
The Second Affiliated Hospital, Wenzhou Medical University, Wenzhou
RECRUITING
Chongqing General Hospital, Chongqing
RECRUITING
Renmin Hospital of Wuhan University, Wuhan
NOT_YET_RECRUITING
The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou
NOT_YET_RECRUITING
West China Hospital of Sichuan University, Chengdu
NOT_YET_RECRUITING
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER